Zobrazit minimální záznam

Engine shutdown: Migrastatic strategies and prevention of metastases

dc.contributor.authorRaudenská, Martina
dc.contributor.authorPetrláková, Kateřina
dc.contributor.authorJuriňáková, Tamara
dc.contributor.authorLeischner Fialová, Jindřiška
dc.contributor.authorFojtů, Michaela
dc.contributor.authorJakubek, Milan
dc.contributor.authorRösel, Daniel
dc.contributor.authorBrábek, Jan
dc.contributor.authorMasařík, Michal
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.14178/1810
dc.description.abstractMost cancer-related deaths among patients with solid tumors are caused by metastases. Migrastatic strategies represent a unique therapeutic approach to prevent all forms of cancer cell migration and invasion. Because the migration machinery has been shown to promote metastatic dissemination, successful migrastatic therapy may reduce the need for high-dose cytotoxic therapies that are currently used to prevent the risk of metastatic dissemination. In this review we focus on anti-invasive and antimetastatic strategies that hold promise for the treatment of solid tumors. The best targets for migrastatic therapy would be those that are required by all forms of motility, such as ATP availability, mitochondrial metabolism, and cytoskeletal dynamics and cell contractility.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.1016/j.trecan.2023.01.001
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titleEngine shutdown: Migrastatic strategies and prevention of metastasesen
dcterms.accessRightsembargoedAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2023-10-02T06:15:33Z
dc.subject.keywordcanceren
dc.subject.keywordcancer therapyen
dc.subject.keywordcell migrationen
dc.subject.keywordmetastasisen
dc.subject.keywordmigrastatic therapyen
dc.subject.keywordmitochondria-targeting therapyen
dc.subject.keywordnanocarriersen
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/EF/EF16_019/0000785
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/OP VVV/CZ.02.1.01/0.0/0.0/16_019/0000785
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU21-03-00223
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU21-08-00407
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/GA0/GA/GA21-06873S
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.date.embargoStartDate2023-10-02
dc.date.embargoEndDate2023-03-24
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.1016/j.trecan.2023.01.001
dc.identifier.utWos000995436100001
dc.identifier.eidScopus2-s2.0-85150018857
dc.identifier.obd625867
dc.identifier.pubmed36804341
dc.subject.rivPrimary30000::30200::30204
dc.subject.rivSecondary10000::10600
dcterms.isPartOf.nameTrends in Cancer
dcterms.isPartOf.issn2405-8033
dcterms.isPartOf.journalYear2023
dcterms.isPartOf.journalVolume9
dcterms.isPartOf.journalIssue4
uk.faculty.primaryId115
uk.faculty.primaryNamePřírodovědecká fakultacs
uk.faculty.primaryNameFaculty of Scienceen
uk.faculty.secondaryId108
uk.faculty.secondaryName1. lékařská fakultacs
uk.faculty.secondaryNameFirst Faculty of Medicineen
uk.department.primaryId1035
uk.department.primaryNameKatedra buněčné biologiecs
uk.department.primaryNameDepartment of Cell Biologyen
uk.department.secondaryId100025448551
uk.department.secondaryNameBIOCEV 1. LF UKcs
uk.department.secondaryNameBIOCEVen
dc.description.pageRange293-308
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::přehledový článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::summarizing articleen
dc.type.obdHierarchyCode73::152::205en
uk.displayTitleEngine shutdown: Migrastatic strategies and prevention of metastasesen


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam